General practice · free tool
Guideline Finder
The guidelines and RACGP statements your exam answers should name: what each recommends, a sentence you can write to cite it, what changed recently and the outdated answer to avoid. Quiz yourself, flip flashcards, print a cheat sheet. Free, no sign-up.
40 guidelines · 8 from RACGP · 16 recently changed · checked 2026-11
You know 0%
RACGP exam guideline cheat sheet · checked 2026-11 · fellowshipready.com.au
Preventive care: what to screen for and when (Red Book): Guidelines for preventive activities in general practice (the Red Book) (RACGP, 10th edition (2024)). The 10th edition grades its recommendations with GRADE, replacing the older NHMRC FORM approach. Cancer screening is now split into topics for each cancer, with new topics for lung, pancreatic, thyroid and bladder cancer. New topics include hepatitis B and C, anxiety, eating disorders, gambling, perinatal mental health, frailty, and sleep. The separate 'middle age' and 'older age' chapters are gone. Age-based advice now sits within each disease topic.
Cardiovascular risk assessment: who, when and which calculator: Australian guideline for assessing and managing cardiovascular disease risk (with the Aus CVD Risk Calculator) (Heart Foundation-led national guideline (Australian Chronic Disease Prevention Alliance), 2023). Assess people without known CVD: everyone aged 45–79, people with diabetes aged 35–79, and First Nations people aged 30–79. First Nations people aged 18–29 should have their individual risk factors assessed. Estimated 5-year risk: high is 10% or more, intermediate is 5% to under 10%, and low is under 5%. Risk can be reclassified up or down for ethnicity, coronary artery calcium score, family history, eGFR/uACR and severe mental illness.
Hypertension: confirming diagnosis, first-line drugs and targets: Guideline for the diagnosis and management of hypertension in adults (National Heart Foundation of Australia, 2016). If clinic BP is 140/90 or higher, confirm it with ambulatory or home BP monitoring. First-line drugs are an ACE inhibitor or ARB, a calcium channel blocker, or a thiazide diuretic. Beta-blockers are not first line for uncomplicated hypertension, and an ACE inhibitor should not be combined with an ARB. Target below 140/90 in uncomplicated hypertension. A systolic target below 120 can be considered in selected high-risk patients, with close monitoring. Base treatment decisions on absolute CVD risk as well as the BP level.
Heart failure with reduced ejection fraction: the four pillars: Consensus statement on the current pharmacological prevention and management of heart failure (Australian expert consensus (Sindone et al., Medical Journal of Australia), 2022 (MJA 217(4))). In HFrEF, start four drug classes early rather than one at a time: an ARNI (preferred) or ACE inhibitor, a beta-blocker, an MRA, and an SGLT2 inhibitor. Use an ACE inhibitor instead of an ARNI if hypotension is a problem, and consider switching to an ARNI later. Start the beta-blocker once a congested patient is euvolaemic, and titrate all four classes to the maximum tolerated dose. Dapagliflozin or empagliflozin is recommended across all types of heart failure, including HFpEF.
Asthma: initial treatment in adults and adolescents: Australian Asthma Handbook (National Asthma Council Australia, Version 3.0 (2025)). For people aged 12 and over, everyone with asthma should be on an inhaled corticosteroid. SABA alone is no longer recommended. As-needed budesonide–formoterol is the recommended first-line treatment after diagnosis, and anti-inflammatory relievers are preferred over SABA relievers. For diagnosis, FeNO testing is now recommended alongside spirometry for children aged 6–11 and for adolescents and adults. Refer to a specialist if asthma remains uncontrolled on a medium-dose ICS regimen.
COPD: confirming the diagnosis and stepwise management: The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease (Lung Foundation Australia and Thoracic Society of Australia and New Zealand, Version 2.78 (December 2025)). Diagnosis requires spirometry showing a post-bronchodilator FEV1/FVC below 0.7. Do not diagnose COPD on symptoms or imaging alone. Treatment is stepwise: a short-acting reliever, then long-acting bronchodilators (LAMA and/or LABA). Add an ICS mainly for people with repeated exacerbations. Smoking cessation, vaccination and pulmonary rehabilitation are core non-drug treatments, with rehabilitation especially after an exacerbation. COPD-X is updated as a living guideline, so cite the version number.
Type 2 diabetes: targets and drug choices in general practice: Management of type 2 diabetes: A handbook for general practice (RACGP, 2024 edition (published November 2024; updated 2025)). The general HbA1c target is 7% (53 mmol/mol) or below, individualised to the person. BP: the general target is 140/90 or below, and below 130/80 with CKD. In secondary prevention, aim for LDL below 1.4 mmol/L and at least a 50% reduction. Metformin remains the usual first drug. SGLT2 inhibitors and GLP-1 receptor agonists are chosen for their heart and kidney benefits in people with CVD, CKD or heart failure. RSV vaccination for people over 60 is now listed as recommended.
Chronic kidney disease: detection and management in primary care: Chronic Kidney Disease (CKD) Management in Primary Care (Kidney Health Australia, 5th edition (2024)). Test at-risk adults (diabetes, hypertension, CVD, family history, smoking, obesity, First Nations people aged 18 and over) with eGFR, urine ACR and BP. CKD is staged on both eGFR and albuminuria, so always order a urine ACR as well as eGFR. The 5th edition sets out a stepwise approach to lowering albuminuria and medicines that slow CKD progression and reduce CV risk, including ACE inhibitors or ARBs and SGLT2 inhibitors. It includes revised algorithms for detection and nephrology referral, the Aus CVD Risk Calculator in CKD, and guidance on culturally safe kidney care.
Osteoporosis: treatment choice and stopping denosumab: Osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age (RACGP and Healthy Bones Australia, 3rd edition (2024)). This is the first update since 2017. Drugs are grouped as antiresorptive or osteoanabolic, and 'very high' or 'imminent' fracture risk is defined. Use fracture risk assessment tools when screening and case-finding. Stopping denosumab carries a risk of rebound vertebral fractures, so plan follow-on therapy rather than simply stopping. Strontium has been removed as an option, and calcium and vitamin D status should be optimised.
Cervical screening, self-collection and post-coital bleeding: National Cervical Screening Program clinical guidelines (Cancer Council Australia (endorsed by RACGP and RANZCOG), Current online guidelines (universal self-collection since July 2022)). Asymptomatic people with a cervix aged 25–74 have an HPV test every 5 years. It can be self-collected or clinician-collected, with equal accuracy. HPV 16/18 means referral for colposcopy. Other HPV types found on a self-collected sample need a clinician-collected LBC. Symptoms such as post-coital or other unexplained bleeding follow the diagnostic pathway with a clinician-collected co-test, not routine screening or self-collection. People aged 70–74 with a negative HPV test can exit the program.
Menopausal hormone therapy: choosing a regimen: AMS Guide to MHT/HRT Doses (Australia) (Australasian Menopause Society, Information sheet (2024, March 2025 revision)). Use cyclic MHT in perimenopause or within 12 months of the last period. Use continuous combined MHT after 12 months without a period. Anyone with a uterus who takes systemic oestrogen needs a progestogen or a levonorgestrel IUD. Vaginal oestrogen alone does not need a progestogen. On continuous combined therapy, investigate bleeding that continues after the first 6 months.
Rh D immunoglobulin after early pregnancy loss: Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care (National Blood Authority, 2024). Check blood group and antibody screen early in pregnancy, no later than 10 weeks. A Rh D negative woman without preformed anti-D should get 250 IU after miscarriage, termination, ectopic or molar pregnancy, or CVS in the first 12 weeks. Routine use after medical termination before 10 weeks is not supported by the evidence and is left to clinical discretion. If gestational age is uncertain, consider giving Rh D Ig and arranging an ultrasound to confirm dates.
Vaccines in pregnancy: pertussis, influenza and RSV: The Australian Immunisation Handbook (ATAGI / Australian Government Department of Health, Digital edition (continuously updated)). Influenza vaccine can be given at any stage, in every pregnancy. Give dTpa (pertussis) at 20–32 weeks in every pregnancy. If missed, it can still be given later. A dose given at 13–20 weeks does not need repeating. Maternal RSV vaccine (Abrysvo) is recommended from 28 weeks' gestation. Live vaccines are contraindicated in pregnancy.
Perinatal depression and anxiety: screening and care: Mental Health Care in the Perinatal Period: Australian Clinical Practice Guideline (Centre of Perinatal Excellence (COPE), 2023). This is the national perinatal mental health guideline. The 2023 edition updates the 2017 guideline. Screen routinely for depression and anxiety with the EPDS in pregnancy and again in the postnatal period, alongside a psychosocial assessment of risk factors. It covers assessment and treatment of depression, anxiety and severe mental illness in pregnancy and the year after birth.
Alcohol use disorder: withdrawal and relapse-prevention drugs: Guidelines for the Treatment of Alcohol Problems (Australian Government-funded expert guideline (Haber et al., University of Sydney), 2021). Use the AUDIT to screen in primary care and hospitals. AUDIT-C is an alternative for community screening. Most withdrawal can be managed as an outpatient with support, using a tapering diazepam regimen with staged daily supply. Acamprosate helps maintain abstinence and naltrexone prevents relapse to heavy drinking (both Level A). Disulfiram is only for supervised, motivated patients. Baclofen and topiramate (off-label) have some evidence but should not be first line.
Allergy prevention: introducing peanut and egg: ASCIA Guidelines: Infant Feeding and Allergy Prevention (Australasian Society of Clinical Immunology and Allergy (ASCIA), 2020 (format updated 2024)). Start solids at around 6 months, but not before 4 months, while breastfeeding continues. Introduce peanut, cooked egg, dairy and wheat in the first year, including for high-risk infants. Do not delay them. Partially or extensively hydrolysed formula is not recommended to prevent allergy.
Bronchiolitis: what not to do and when to give oxygen: Australasian Bronchiolitis Guideline: 2025 Update (PREDICT Network, 2025). Diagnosis is clinical. Routine chest X-ray, bloods and viral testing are not recommended. Do not routinely use salbutamol, adrenaline, corticosteroids, hypertonic saline, antibiotics or chest physiotherapy. Consider oxygen if SpO2 stays below 90% (infants 6 weeks or older) or below 92% (under 6 weeks, or with an underlying condition). If oral intake is poor, nasogastric fluids are preferred. New in 2025: guidance on RSV prevention, including nirsevimab and maternal RSV vaccination.
ADHD: diagnosis and first-line treatment: Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder (ADHD) (Australian ADHD Professionals Association (AADPA), 1st edition (October 2022), NHMRC-approved). This is Australia's first NHMRC-approved ADHD guideline. It covers identification, diagnosis and treatment across the lifespan. For school-aged children and adults, stimulant medication (methylphenidate, dexamfetamine or lisdexamfetamine) is a first-line option, alongside non-drug supports. Non-drug interventions such as parent training come first for young children. Monitor medication effects, including growth, appetite, BP and heart rate.
Autism: how assessment and diagnosis should be done: National Guideline for the assessment and diagnosis of autism in Australia (Autism CRC, 2nd edition (2023 update; 2018 edition NHMRC-approved)). Assessment combines a comprehensive needs assessment (including functioning and strengths) with a diagnostic evaluation. The 2023 update renamed the single-clinician pathway the 'Lead Practitioner Diagnostic Evaluation': one clinician leads and draws on input from others. The update has fewer recommendations and adds neurodiversity-affirming practice. Findings should identify support needs, not only give a diagnostic label.
Severe BPSD in residential aged care: short-term antipsychotics: RACGP aged care clinical guide (Silver Book) (RACGP, 5th edition (2019)). Non-drug measures come first. Risperidone (PBS-listed) is used only after they have been tried and failed, and after looking for reversible causes. Reserve antipsychotics for severe agitation or aggression with a risk of harm, or for distressing psychosis. Start at a low dose and review within a week. Plan to wean and stop as soon as possible, preferably before 12 weeks, and review at least 3-monthly. Get and document consent from the patient or their substitute decision-maker, including the risks discussed.
Dementia: cholinesterase inhibitors and antipsychotics: Clinical Practice Guidelines and Principles of Care for People with Dementia (NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People (NHMRC-approved), 2016). Use non-drug approaches first for BPSD, and look for and treat pain. Cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine can be used in mild to moderate Alzheimer disease. They should not be prescribed for mild cognitive impairment. Avoid antipsychotics for mild to moderate BPSD because they raise the risk of stroke and death. They may be offered for severe distress or risk to others. Review antipsychotics every 4–12 weeks and consider stopping them.
Delirium: screening and the limited role of antipsychotics: Delirium Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2021 (revised)). The standard has eight quality statements covering screening, assessment, prevention, management and follow-up. Screen people at risk (for example, older people or those with cognitive impairment) for delirium when they present. Prevention and management rely on non-drug, multicomponent strategies. Antipsychotics are not routinely used to prevent or treat delirium. Use them only for severe distress or risk, at the lowest dose for the shortest time.
Suspected melanoma: biopsy and referral: Optimal care pathway for people with melanoma (Cancer Council Australia (Optimal Care Pathways), 2nd edition (2021)). If melanoma is suspected, do an excisional biopsy of the whole lesion with a 2 mm margin, or refer. Once histology confirms melanoma, re-excise with the recommended margins. Discuss sentinel lymph node biopsy for melanomas thicker than 1 mm, or thicker than 0.75 mm with high-risk features such as ulceration.
Knee and hip osteoarthritis: what to avoid: Guideline for the management of knee and hip osteoarthritis (RACGP, 2nd edition (2018)). Non-drug management, such as exercise and weight management, should be optimised first. Oral NSAIDs, including COX-2 inhibitors, get a conditional recommendation for: lowest effective dose, short trial, and monitoring of GI, renal and CV harms. Paracetamol is neutral (neither for nor against). The average benefit is too small to be clinically meaningful. There is a strong recommendation against oral and transdermal opioids.
Acute low back pain: imaging and medicines: Low Back Pain Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2022). Assess for serious or specific pathology and screen for psychosocial factors early. Reserve imaging for suspected serious or specific pathology. Encourage staying active and returning to usual activities, including work. Use medicines to enable activity. Avoid anticonvulsants, benzodiazepines and antidepressants for low back pain. Consider opioids only in carefully selected patients, at the lowest dose for the shortest time.
Bowel cancer screening from age 45: National Bowel Cancer Screening Program (Australian Government Department of Health, Eligible ages 45–74 (45–49 from 1 July 2024)). The program screens people aged 45–74 with a free iFOBT every 2 years. People aged 45–49 can request their first kit. People aged 50–74 receive kits automatically by mail. The test uses two samples from different bowel motions. A positive result needs referral for colonoscopy. This program is for asymptomatic people. Symptomatic patients need diagnostic investigation.
Hepatitis C: who to treat and who can prescribe: Australasian recommendations for the management of hepatitis C virus infection: a consensus statement (Gastroenterological Society of Australia / ASHM and partners, 2022). Consider all adults with HCV for direct-acting antiviral treatment. Experienced medical practitioners, including GPs, and nurse practitioners can prescribe treatment. Pangenotypic regimens (sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) are standard. Assess for cirrhosis (for example with APRI) before treatment. Confirm cure with an HCV RNA test 12 weeks after treatment, and keep testing people at ongoing risk for reinfection.
Minor stroke and high-risk TIA: dual antiplatelet therapy: Australian and New Zealand Living Clinical Guidelines for Stroke Management (Stroke Foundation, Living guideline (continuously updated)). For minor ischaemic stroke or high-risk TIA, start aspirin plus clopidogrel within 24 hours and continue short term (about 3 weeks). This is a strong recommendation. Ticagrelor plus aspirin for 30 days is an alternative. Assess and image TIA and minor stroke urgently, because early stroke risk is highest in the first days. This is a living guideline, so cite it as the current online version.
Fitness to drive: who decides and the doctor's role: Assessing Fitness to Drive for commercial and private vehicle drivers (Austroads and National Transport Commission, 2022 edition (in effect from 22 June 2022)). The driver licensing authority makes licensing decisions. The health professional assesses the patient and advises it. Private and commercial vehicle standards differ, and commercial standards are stricter. Drivers have a legal duty to report conditions that affect their driving. A health professional can report directly if there is a public safety concern. The standards apply to conditions such as seizures, syncope, diabetes on insulin, sleep disorders, vision, cognitive impairment and psychiatric illness.
Anaphylaxis: first-line treatment and observation: ASCIA Guidelines: Acute Management of Anaphylaxis (Australasian Society of Clinical Immunology and Allergy (ASCIA), 2023 (content updated January 2023)). Give IM adrenaline 1:1,000 at 0.01 mg/kg (maximum 0.5 mg) into the outer mid-thigh. Repeat every 5 minutes if there is no response. Lay the patient flat and do not let them stand or walk. They may sit with legs outstretched if breathing is difficult. Antihistamines and corticosteroids are not first line and must never replace or delay adrenaline. Observe for at least 4 hours after the last adrenaline dose, and overnight for severe or protracted reactions.
Sepsis: timing of antibiotics and early resuscitation: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock (Society of Critical Care Medicine and European Society of Intensive Care Medicine, 2021). For possible septic shock or a high likelihood of sepsis, give antimicrobials ideally within 1 hour of recognition. For possible sepsis without shock, investigate quickly and give antibiotics within 3 hours if infection is still a concern. Give at least 30 mL/kg of crystalloid in the first 3 hours for hypoperfusion, preferring balanced crystalloids. Use noradrenaline first line, with a MAP target of 65. Do not use qSOFA on its own as a screening tool.
Palliative care: anticipatory prescribing and deprescribing: Therapeutic Guidelines: Palliative Care (Therapeutic Guidelines Ltd, 2024 update (published December 2024)). Bring in palliative care early, alongside disease-modifying treatment, with care planned around the person's goals and prognosis. Start deprescribing early, using shared decision-making. Anticipatory prescribing for the last days of life uses drugs available on the PBS Prescriber Bag. DOACs are acceptable for treating VTE in palliative patients. VTE prophylaxis is generally not recommended in the last weeks of life.
Aboriginal and Torres Strait Islander preventive health checks: National Guide to preventive healthcare for Aboriginal and Torres Strait Islander people (RACGP and NACCHO, 4th edition (2024)). This is the reference for the annual health assessment (MBS item 715), organised by age and topic, with an actions-based format. Start calculator-based CVD risk assessment at age 30, and assess individual risk factors from age 18. It is developed with community-controlled health services and emphasises culturally safe, community-led care. The 4th edition was launched in November 2024 and replaces the 3rd edition.
Acute rheumatic fever: secondary prophylaxis: The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (RHDAustralia (Menzies School of Health Research), 3.2 edition (March 2022)). Secondary prophylaxis with benzathine benzylpenicillin G is usually given every 28 days. Selected high-risk patients may need it every 21 days. In high-risk populations the Jones criteria are applied with lower diagnostic thresholds. Secondary prophylaxis is continued for a defined duration based on age and severity of heart disease. Notify ARF and RHD where required and add patients to the jurisdictional register.
Safe drinking advice for adults, young people and pregnancy: Australian guidelines to reduce health risks from drinking alcohol (NHMRC, 2020). Healthy adults should drink no more than 10 standard drinks a week and no more than 4 on any one day. People under 18 should not drink alcohol. Not drinking is advised when pregnant or planning a pregnancy, and not drinking is safest while breastfeeding.
Smoking cessation: pharmacotherapy and nicotine vapes: Supporting smoking cessation: A guide for health professionals (RACGP, 2nd edition (2021; updated for October 2024 vaping changes)). Give brief advice to everyone who smokes and offer follow-up and referral to telephone call-back counselling. For nicotine dependence, offer pharmacotherapy with behavioural support. Varenicline is strongly recommended, and combination NRT (patch plus oral form) beats a single form. Bupropion is less effective, and nortriptyline is second line because of its adverse effects. Nicotine vaping products are a conditional option only after first-line therapy has failed, using shared decision-making.
Lung cancer screening: eligibility for low-dose CT: National Lung Cancer Screening Program (Australian Government Department of Health, Program guidelines (2025)). Eligible people are aged 50–70, have no symptoms of lung cancer, currently smoke or quit within the past 10 years, and have at least 30 pack-years. The screening test is low-dose CT, and every scan needs a new request. Next steps follow the risk category in the radiology report: rescreen in 24, 12, 6 or 3 months, or refer to a respiratory physician or lung cancer MDT. Symptomatic patients need diagnostic investigation, not screening.
Mandatory notification of an impaired colleague you are treating: Guidelines: Mandatory notifications about registered health practitioners (Ahpra and the National Boards, Current guidelines (2020)). There are four types of concern: impairment, intoxication while practising, significant departure from accepted professional standards, and sexual misconduct. Treating practitioners have a higher threshold. For impairment, intoxication or departure from standards, they must notify only if there is a substantial risk of harm to the public. For sexual misconduct the threshold is lower: a reasonable belief that it has occurred, is occurring or is at risk of occurring. In WA, treating practitioners are exempt from the mandatory requirement but may notify voluntarily.
Professional conduct: telehealth, cultural safety and social media: Good medical practice: a code of conduct for doctors in Australia (Medical Board of Australia, October 2020). The code applies to all consultations, including telehealth and online or remote prescribing. It defines cultural safety for Aboriginal and Torres Strait Islander Peoples and extends culturally safe practice to all communities. It sets zero tolerance of discrimination, bullying and sexual harassment. It covers public comment and social media.
Opioid prescribing for chronic non-cancer pain: Prescribing drugs of dependence in general practice, Part C1: Opioids (RACGP, 2017 (minor updates 2020)). Opioids are generally a short-term option, and long-term use should be uncommon. Prescribe the lowest effective dose for the shortest time. Prescribe from one practice (ideally one GP) and dispense from one pharmacy. Schedule regular attempts to reduce the dose for anyone on long-term opioids. Take care with comorbid substance use and benzodiazepines, which increase the risk of harm. Consider a substance use disorder where relevant.
Summaries are written in our own words from each guideline's official page and are for exam study, not clinical use. Guidelines change: check the source before you rely on it.
Try 20 free questions.
RACGP-style questions, marked with a reason for every option. Free account, no card.
Also free: Anatomy Scroller · RACGP exam guides